450 related articles for article (PubMed ID: 16445776)
21. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
Winterfield L; Menter A
Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
[TBL] [Abstract][Full Text] [Related]
22. Calcipotriol induces apoptosis in psoriatic keratinocytes.
Tiberio R; Bozzo C; Pertusi G; Graziola F; Gattoni M; Griffanti P; Boggio P; Colombo E; Leigheb G
Clin Exp Dermatol; 2009 Dec; 34(8):e972-4. PubMed ID: 19758385
[TBL] [Abstract][Full Text] [Related]
23. New development in the treatment of psoriasis--infliximab.
Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
[TBL] [Abstract][Full Text] [Related]
24. The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis.
Adişen E; Gülekon A; Erdem O; Dursun A; Gürer MA
J Eur Acad Dermatol Venereol; 2006 May; 20(5):527-33. PubMed ID: 16684279
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
26. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.
Bovenschen HJ; Van De Kerkhof PC; Gerritsen WJ; Seyger MM
Eur J Dermatol; 2005; 15(6):454-8. PubMed ID: 16280298
[TBL] [Abstract][Full Text] [Related]
27. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
28. Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy.
Eşrefoğlu M; Gül M; Seyhan M
Ultrastruct Pathol; 2006; 30(1):95-102. PubMed ID: 16517475
[TBL] [Abstract][Full Text] [Related]
29. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53 in lesions and unaffected skin of patients with plaque-type and guttate psoriasis: a quantitative comparative study.
Yazici AC; Karabulut AA; Ozen O; Ekşioğlu M; Ustün H
J Dermatol; 2007 Jun; 34(6):367-74. PubMed ID: 17535401
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
32. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
[TBL] [Abstract][Full Text] [Related]
33. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
Malaviya R; Sun Y; Tan JK; Magliocco M; Gottlieb AB
J Drugs Dermatol; 2006 Oct; 5(9):890-3. PubMed ID: 17039656
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe psoriasis with infliximab: report of two cases.
Peternel S; Prpić-Massari L; Guina T; Novak S; Brajac I; Kastelan M
Acta Dermatovenerol Croat; 2009; 17(3):204-6. PubMed ID: 19818221
[TBL] [Abstract][Full Text] [Related]
35. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
36. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
[No Abstract] [Full Text] [Related]
37. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
38. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
39. Infliximab and nephrotic syndrome.
Chin G; Luxton G; Harvey JM
Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.
Smeets TJ; Kraan MC; van Loon ME; Tak PP
Arthritis Rheum; 2003 Aug; 48(8):2155-62. PubMed ID: 12905468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]